Lung CancerBREATH-PANNCT07804017
Exhaled Breath Electronic Nose for Multi-Disease Risk Prescreening
An observational study of Lung Cancer and Pulmonary Nodule, run by The First Affiliated Hospital of Guangzhou Medical University.
Trial summary
This prospective multicenter observational study will evaluate whether an electronic nose that analyzes patterns in exhaled breath can be developed as a noninvasive tool for early risk prescreening across several disease areas. The study will enroll up to 20,000 adults from hospitals and health examination centers. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Lung Cancer, Pulmonary Nodule, Chronic Respiratory Disease
- What is being tested?
- Electronic-Nose Breath Assessment
- How many people
- 20,000 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to 1 Sep 2028
- How long will I take part?
- 2 Years
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adults aged ≥18 years will be prospectively recruited from participating hospitals and health examination centers. The study population will include individuals undergoing routine health examinations, opportunistic screening, or planned disease-specific screening or clinical evaluation. Clinically stable volunteers will be enrolled in the methodological standardization cohort, while the multi-disease risk prescreening cohort will include consecutively recruited intended-use populations with available routine reference screening or sufficient clinical information for reference-status determination. Patients with suspected or confirmed disease may also be included for model development or exploratory analyses but will not replace the intended-use population for locked external evaluation.
Who may be able to join
- Age ≥18 years. Able to provide informed consent and willing to sign written informed consent. Able to understand and follow standardized breathing instructions and safely complete seated exhaled-breath sampling.
- Breath sampling is considered by the study physician not to delay or interfere with necessary routine clinical care or health examination.
- Routine reference screening results are available for at least one prespecified disease module, or sufficient clinical information is available to determine the corresponding reference status.
- Willing to permit authorized study personnel to review relevant medical records and follow-up information within the scope of ethical approval.
Who cannot join
- Refusal to participate, inability to provide valid informed consent, or inability to reliably comply with study procedures.
- Acute respiratory distress, active massive hemoptysis, untreated pneumothorax, significant impairment of consciousness, or any condition for which forced exhalation is considered unsafe by the study physician.
- Requirement for strict airborne isolation when the study site or equipment cannot meet applicable infection-control requirements.
- Recent major surgery, invasive procedure, or other clinical intervention for which the treating physician considers breath sampling should be postponed.
- Vomiting, severe nausea, intense coughing, or other conditions before sampling that substantially increase the risk of aspiration, syncope, or related adverse events.
- Acute oral or nasopharyngeal conditions, or recent food intake, smoking, alcohol consumption, vigorous exercise, or other factors that prevent standardized breath sampling; such participants may be rescheduled rather than permanently excluded.
- Key reference-standard information is unavailable and is not expected to be obtained through routine follow-up.
- Any other condition considered by the investigator to make participation inappropriate.
About this study
Official title: Development and Validation of an Exhaled Breath Electronic Nose Platform for Multi-Disease Risk Prescreening: A Prospective Multicenter Study
This prospective multicenter observational study will evaluate whether an electronic nose that analyzes patterns in exhaled breath can be developed as a noninvasive tool for early risk prescreening across several disease areas. The study will enroll up to 20,000 adults from hospitals and health examination centers. It will first establish a standardized breath-sampling and quality-control procedure and assess repeatability across breathing maneuvers, devices, centers, and time. It will then develop and independently evaluate risk prescreening models for prespecified disease modules, including lung cancer/clinically significant pulmonary nodules, chronic respiratory diseases, and metabolic/endocrine diseases, with additional exploratory modules involving liver, kidney, cardiovascular, and systemic inflammatory/infectious/immune conditions.
The electronic-nose results are for research only and will not be reported to participants or clinicians or used to change routine screening, diagnosis, or treatment. Disease reference status will be determined from examinations, laboratory tests, imaging, pathology, pulmonary function testing, specialist assessments, or follow-up that are already performed as part of routine care. The study will evaluate screening sensitivity, specificity, false-negative rate, predictive values, calibration, and performance across different centers, devices, and time periods.
Read the detailed description
This is an investigator-initiated, prospective, multicenter, observational, staged platform cohort study involving hospitals and health examination centers. The study is designed to establish a standardized and traceable exhaled-breath electronic-nose platform and to evaluate its potential role as a first-line risk prescreening tool rather than as a stand-alone diagnostic test. Up to 20,000 participants will be prospectively enrolled.
The first stage is a methodological standardization and cross-center consistency cohort of approximately 500 clinically stable participants. Each participant will complete three predefined breathing maneuvers in randomized order: end-expiratory sampling without breath holding, sampling after a 5-second breath hold, and sampling after a 10-second breath hold. Each maneuver will be repeated twice. At least 250 participants will undergo repeat sampling at 7±3 days and 30±7 days, and selected participants will undergo cross-device or cross-center bridge sampling. Repeatability, within-participant variability, sample validity, tolerability, and device/center consistency will be evaluated to determine the locked sampling and quality-control procedure for the subsequent large cohort.
The second stage is a multi-disease risk prescreening cohort of approximately 19,500 participants. Prespecified major disease modules include lung cancer/clinically significant pulmonary nodules, chronic respiratory diseases, and metabolic/endocrine diseases. Liver, kidney, cardiovascular, and systemic inflammatory/infectious/immune conditions will be evaluated as secondary or exploratory modules. Because participants may have more than one condition, disease outcomes will be modeled using a multi-label rather than mutually exclusive classification framework.
Approximately 12,000 participants will be used for model development, approximately 3,000 for temporally independent evaluation, and approximately 4,500 from prespecified held-out centers for whole-center external evaluation. Preprocessing procedures, model architecture, features, module-specific screening thresholds, and the overall screening rule will be locked before evaluation data are analyzed. Temporal and whole-center external evaluation datasets will not be used for model tuning or threshold selection.
Reference status for each disease module will be determined from routine clinical or health-screening information, including laboratory testing, pulmonary function testing, imaging, pathology, specialist assessment, and routine follow-up as applicable. The study will not require additional CT scans, blood sampling, endoscopy, surgery, or other invasive procedures solely to establish the reference standard. Participants with insufficient reference information will not be included in the corresponding primary accuracy analysis.
Primary evaluation of the locked risk prescreening models will include sensitivity, specificity, false-negative rate, and 95% confidence intervals at fixed thresholds. Positive predictive value, negative predictive value, and screening-positive rate will also be reported in consecutively recruited intended-use populations without case enrichment. Secondary analyses will assess AUROC, AUPRC, likelihood ratios, Brier score, calibration, decision-curve net benefit, subgroup performance, and transportability across centers, devices, and acquisition periods.
A nested longitudinal/repeat-sampling cohort of approximately 600-1,000 participants, with an upper limit of 3,000, may undergo repeat breath sampling at routine preoperative/postoperative, treatment, follow-up, or health examination visits to explore within-person temporal changes in breath profiles. These analyses are exploratory and are not part of the primary risk prescreening conclusions.
- Conditions
- Lung Cancer, Pulmonary Nodule, Chronic Respiratory Disease, Metabolic Disease, Endocrine Disease
- Being tested
- Electronic-Nose Breath Assessment
- Keywords
- Electronic Nose, Exhaled Breath, Multi-Disease Risk Prescreening, Artificial Intelligence, Machine Learning, Noninvasive Screening
- Medical subject headings
- Lung Neoplasms, Metabolic Diseases, Endocrine System Diseases
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Electronic-Nose Breath AssessmentDiagnostic test
Participants will provide standardized exhaled-breath samples for electronic-nose analysis. The electronic-nose system records multichannel gas-sensor responses together with flow, temperature, humidity, and process information. In the methodological standardization cohort, participants will undergo repeated sampling using three predefined breathing maneuvers to assess repeatability and cross-center/device consistency. In the multi-disease risk prescreening cohort, participants will undergo the locked standardized sampling procedure for development and independent evaluation of disease risk prescreening models. Electronic-nose results are for research purposes only and will not be reported to participants or clinicians or used to alter routine screening, diagnosis, or treatment.
| Study group | Role | What they receive |
|---|---|---|
| Methodological Standardization Cohort | Approximately 500 clinically stable participants will undergo standardized exhaled-breath sampling to evaluate methodological repeatability and cross-center/device consistency. Participants will complete three predefined breathing maneuvers in randomized order, with each maneuver repeated twice. At least 250 participants will undergo repeat sampling at 7±3 days and 30±7 days, and selected participants may undergo cross-device or cross-center bridge sampling. Receives: Diagnostic Test: Electronic-Nose Breath Assessment | |
| Multi-Disease Risk Prescreening Cohort | Approximately 19,500 participants will undergo standardized exhaled-breath electronic-nose assessment before the corresponding routine reference screening results are available. The cohort will be used to develop and independently evaluate multi-label risk prescreening models for prespecified disease modules, including lung cancer/clinically significant pulmonary nodules, chronic respiratory diseases, and metabolic/endocrine diseases, with additional secondary or exploratory disease modules. Receives: Diagnostic Test: Electronic-Nose Breath Assessment |
What is being measured
The primary outcome is the main question the study is designed to answer.
Same-Day Repeatability of the Locked Exhaled-Breath Sampling Method
Same-day repeatability of electronic-nose measurements obtained using the locked exhaled-breath sampling method will be assessed using the intraclass correlation coefficient (ICC) with 95% confidence intervals based on repeated measurements collected from the same participant during the same visit.
Measured: During the baseline sampling visit; repeated samples are collected approximately 3-5 minutes apart.
Screening Performance of the Locked Multi-Disease Risk Prescreening Models
For each prespecified major disease module meeting the required event-number threshold, sensitivity, specificity, false-negative rate, and corresponding 95% confidence intervals will be estimated at the locked screening threshold. Positive predictive value, negative predictive value, and screening-positive rate will additionally be reported in consecutively recruited, non-enriched intended-use populations. Temporal and whole-center external evaluations will be reported separately.
Measured: From index breath sampling to completion and adjudication of the corresponding routine reference screening or clinical assessment, up to 16 months after index breath sampling.
Secondary outcomes (5)
Area Under the Receiver Operating Characteristic Curve of the Locked Risk Prescreening Models
For each prespecified major disease module meeting the required event-number threshold, discrimination of the locked risk prescreening model will be assessed using the area under the receiver operating characteristic curve (AUROC) with 95% confidence intervals. Temporal and whole-center external evaluations will be reported separately.
Measured: From index breath sampling to completion and adjudication of the corresponding routine reference screening or clinical assessment, up to 16 months after index breath sampling.
Downstream Examination Burden of the Any-Major-Module-Positive Rule
The downstream examination burden of the prespecified "any major module positive" rule will be estimated as the number of participants per 1,000 individuals screened who would be referred for further disease-specific screening or clinical assessment under the locked rule.
Measured: From index breath sampling to completion and adjudication of the corresponding routine reference screening or clinical assessment, up to 16 months after index breath sampling.
Valid-Sample Rate of Standardized Exhaled-Breath Sampling
The valid-sample rate will be defined as the proportion of completed exhaled-breath sampling procedures that meet the prespecified locked quality-control criteria for a valid electronic-nose sample.
Measured: During each exhaled-breath sampling visit.
Short-Term Stability of the Locked Exhaled-Breath Sampling Method
Short-term stability of electronic-nose measurements obtained using the locked sampling method will be assessed using the intraclass correlation coefficient (ICC) with 95% confidence intervals across baseline and repeat measurements at 7±3 days and 30±7 days.
Measured: From baseline sampling through the 30±7-day repeat-sampling visit.
Adverse Event Rate During or Immediately After Exhaled-Breath Sampling
The adverse event rate will be defined as the proportion of participants experiencing one or more adverse events during or immediately after exhaled-breath sampling, including cough, dyspnea, chest tightness, dizziness, nausea, syncope, hypoxemia, or other adverse events recorded in association with the sampling procedure.
Measured: During and immediately after each exhaled-breath sampling procedure.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted4 Sep 2026
- Study start1 Sep 2026 (estimated)
- Primary completion1 Jan 2028 (estimated)
- Study completion1 Sep 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancerStudies of the same condition, open and under way.
- More trials run by The First Affiliated Hospital of Guangzhou Medical UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 20,000 participants (estimated)
- Target duration
- 2 Years
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jianxing He, The First Affiliated Hospital of Guangzhou Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07804017
- Sponsor's protocol ID
- BREATH-PAN-01
- Acronym
- BREATH-PAN
- Status last verified
- Aug 2026
- First submitted
- 15 Aug 2026
- Last updated
- 4 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Development and Validation of an Exhaled Breath Electronic Nose Platform for Multi-Disease Risk Prescreening: A Prospective Multicenter Study
- ClinicalTrials.gov ID
- NCT07804017
- Acronym / sponsor ID
- BREATH-PAN / BREATH-PAN-01
- Conditions
- Lung Cancer, Pulmonary Nodule, Chronic Respiratory Disease, Metabolic Disease, Endocrine Disease
- Keywords
- Electronic Nose, Exhaled Breath, Multi-Disease Risk Prescreening, Artificial Intelligence, Machine Learning, Noninvasive Screening
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 20,000 participants (estimated)
- Lead sponsor
- The First Affiliated Hospital of Guangzhou Medical UniversityUniversity, hospital or other
- Study start
- 1 Sep 2026 (estimated)
- Primary completion
- 1 Jan 2028 (estimated)
- Study completion
- 1 Sep 2028 (estimated)
- First posted
- 4 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective multicenter observational study will evaluate whether an electronic nose that analyzes patterns in exhaled breath can be developed as a noninvasive tool for early risk prescreening across several disease areas. The study will enroll up to 20,000 adults from hospitals and health examination centers. It will first establish a standardized breath-sampling and quality-control procedure and assess repeatability across breathing maneuvers, devices, centers, and time. It will then develop and independently evaluate risk prescreening models for prespecified disease modules, including lung cancer/clinically significant pulmonary nodules, chronic respiratory diseases, and metabolic/endocrine diseases, with additional exploratory modules involving liver, kidney, cardiovascular, and systemic inflammatory/infectious/immune conditions.
The electronic-nose results are for research only and will not be reported to participants or clinicians or used to change routine screening, diagnosis, or treatment. Disease reference status will be determined from examinations, laboratory tests, imaging, pathology, pulmonary function testing, specialist assessments, or follow-up that are already performed as part of routine care. The study will evaluate screening sensitivity, specificity, false-negative rate, predictive values, calibration, and performance across different centers, devices, and time periods.
Detailed description
This is an investigator-initiated, prospective, multicenter, observational, staged platform cohort study involving hospitals and health examination centers. The study is designed to establish a standardized and traceable exhaled-breath electronic-nose platform and to evaluate its potential role as a first-line risk prescreening tool rather than as a stand-alone diagnostic test. Up to 20,000 participants will be prospectively enrolled.
The first stage is a methodological standardization and cross-center consistency cohort of approximately 500 clinically stable participants. Each participant will complete three predefined breathing maneuvers in randomized order: end-expiratory sampling without breath holding, sampling after a 5-second breath hold, and sampling after a 10-second breath hold. Each maneuver will be repeated twice. At least 250 participants will undergo repeat sampling at 7±3 days and 30±7 days, and selected participants will undergo cross-device or cross-center bridge sampling. Repeatability, within-participant variability, sample validity, tolerability, and device/center consistency will be evaluated to determine the locked sampling and quality-control procedure for the subsequent large cohort.
The second stage is a multi-disease risk prescreening cohort of approximately 19,500 participants. Prespecified major disease modules include lung cancer/clinically significant pulmonary nodules, chronic respiratory diseases, and metabolic/endocrine diseases. Liver, kidney, cardiovascular, and systemic inflammatory/infectious/immune conditions will be evaluated as secondary or exploratory modules. Because participants may have more than one condition, disease outcomes will be modeled using a multi-label rather than mutually exclusive classification framework.
Approximately 12,000 participants will be used for model development, approximately 3,000 for temporally independent evaluation, and approximately 4,500 from prespecified held-out centers for whole-center external evaluation. Preprocessing procedures, model architecture, features, module-specific screening thresholds, and the overall screening rule will be locked before evaluation data are analyzed. Temporal and whole-center external evaluation datasets will not be used for model tuning or threshold selection.
Reference status for each disease module will be determined from routine clinical or health-screening information, including laboratory testing, pulmonary function testing, imaging, pathology, specialist assessment, and routine follow-up as applicable. The study will not require additional CT scans, blood sampling, endoscopy, surgery, or other invasive procedures solely to establish the reference standard. Participants with insufficient reference information will not be included in the corresponding primary accuracy analysis.
Primary evaluation of the locked risk prescreening models will include sensitivity, specificity, false-negative rate, and 95% confidence intervals at fixed thresholds. Positive predictive value, negative predictive value, and screening-positive rate will also be reported in consecutively recruited intended-use populations without case enrichment. Secondary analyses will assess AUROC, AUPRC, likelihood ratios, Brier score, calibration, decision-curve net benefit, subgroup performance, and transportability across centers, devices, and acquisition periods.
A nested longitudinal/repeat-sampling cohort of approximately 600-1,000 participants, with an upper limit of 3,000, may undergo repeat breath sampling at routine preoperative/postoperative, treatment, follow-up, or health examination visits to explore within-person temporal changes in breath profiles. These analyses are exploratory and are not part of the primary risk prescreening conclusions.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 2 Years
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Methodological Standardization Cohort | – | Diagnostic Test: Electronic-Nose Breath AssessmentApproximately 500 clinically stable participants will undergo standardized exhaled-breath sampling to evaluate methodological repeatability and cross-center/device consistency. Participants will complete three predefined breathing maneuvers in randomized order, with each maneuver repeated twice. At least 250 participants will undergo repeat sampling at 7±3 days and 30±7 days, and selected participants may undergo cross-device or cross-center bridge sampling. |
| Multi-Disease Risk Prescreening Cohort | – | Diagnostic Test: Electronic-Nose Breath AssessmentApproximately 19,500 participants will undergo standardized exhaled-breath electronic-nose assessment before the corresponding routine reference screening results are available. The cohort will be used to develop and independently evaluate multi-label risk prescreening models for prespecified disease modules, including lung cancer/clinically significant pulmonary nodules, chronic respiratory diseases, and metabolic/endocrine diseases, with additional secondary or exploratory disease modules. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adults aged ≥18 years will be prospectively recruited from participating hospitals and health examination centers. The study population will include individuals undergoing routine health examinations, opportunistic screening, or planned disease-specific screening or clinical evaluation. Clinically stable volunteers will be enrolled in the methodological standardization cohort, while the multi-disease risk prescreening cohort will include consecutively recruited intended-use populations with available routine reference screening or sufficient clinical information for reference-status determination. Patients with suspected or confirmed disease may also be included for model development or exploratory analyses but will not replace the intended-use population for locked external evaluation.
Key inclusion criteria (4 listed)
- Age ≥18 years. Able to provide informed consent and willing to sign written informed consent. Able to understand and follow standardized breathing instructions and safely complete seated exhaled-breath sampling.
- Breath sampling is considered by the study physician not to delay or interfere with necessary routine clinical care or health examination.
- Routine reference screening results are available for at least one prespecified disease module, or sufficient clinical information is available to determine the corresponding reference status.
- Willing to permit authorized study personnel to review relevant medical records and follow-up information within the scope of ethical approval.
Key exclusion criteria (8 listed)
- Refusal to participate, inability to provide valid informed consent, or inability to reliably comply with study procedures.
- Acute respiratory distress, active massive hemoptysis, untreated pneumothorax, significant impairment of consciousness, or any condition for which forced exhalation is considered unsafe by the study physician.
- Requirement for strict airborne isolation when the study site or equipment cannot meet applicable infection-control requirements.
- Recent major surgery, invasive procedure, or other clinical intervention for which the treating physician considers breath sampling should be postponed.
- Vomiting, severe nausea, intense coughing, or other conditions before sampling that substantially increase the risk of aspiration, syncope, or related adverse events.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Electronic-Nose Breath AssessmentParticipants will provide standardized exhaled-breath samples for electronic-nose analysis. The electronic-nose system records multichannel gas-sensor responses together with flow, temperature, humidity, and process information. In the methodological standardization cohort, participants will undergo repeated sampling using three predefined breathing maneuvers to assess repeatability and cross-center/device consistency. In the multi-disease risk prescreening cohort, participants will undergo the locked standardized sampling procedure for development and independent evaluation of disease risk prescreening models. Electronic-nose results are for research purposes only and will not be reported to participants or clinicians or used to alter routine screening, diagnosis, or treatment. | Diagnostic test | Methodological Standardization Cohort, Multi-Disease Risk Prescreening Cohort |
Primary outcome
Same-Day Repeatability of the Locked Exhaled-Breath Sampling Method
Time frame: During the baseline sampling visit; repeated samples are collected approximately 3-5 minutes apart.
Same-day repeatability of electronic-nose measurements obtained using the locked exhaled-breath sampling method will be assessed using the intraclass correlation coefficient (ICC) with 95% confidence intervals based on repeated measurements collected from the same participant during the same visit.
Screening Performance of the Locked Multi-Disease Risk Prescreening Models
Time frame: From index breath sampling to completion and adjudication of the corresponding routine reference screening or clinical assessment, up to 16 months after index breath sampling.
For each prespecified major disease module meeting the required event-number threshold, sensitivity, specificity, false-negative rate, and corresponding 95% confidence intervals will be estimated at the locked screening threshold. Positive predictive value, negative predictive value, and screening-positive rate will additionally be reported in consecutively recruited, non-enriched intended-use populations. Temporal and whole-center external evaluations will be reported separately.
5 secondary outcomes
Area Under the Receiver Operating Characteristic Curve of the Locked Risk Prescreening Models
Time frame: From index breath sampling to completion and adjudication of the corresponding routine reference screening or clinical assessment, up to 16 months after index breath sampling.
Downstream Examination Burden of the Any-Major-Module-Positive Rule
Time frame: From index breath sampling to completion and adjudication of the corresponding routine reference screening or clinical assessment, up to 16 months after index breath sampling.
Valid-Sample Rate of Standardized Exhaled-Breath Sampling
Time frame: During each exhaled-breath sampling visit.
Short-Term Stability of the Locked Exhaled-Breath Sampling Method
Time frame: From baseline sampling through the 30±7-day repeat-sampling visit.
Adverse Event Rate During or Immediately After Exhaled-Breath Sampling
Time frame: During and immediately after each exhaled-breath sampling procedure.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Sep 2026.
Related trials for Lung Cancer
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
RecruitingPhase 2/3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
Non-small Cell Lung Cancer
Recruiting
More Than Just X-Rays - Imaging of Chemotherapy-induced Morphological and Functional Cardiovascular and Lung Changes After Childhood ALL and Other Cancers - a Monocentric Late Effects Study (MaximALL)
Acute Lymphatic Leukemia, Lymphoma
RecruitingPhase 1
SW-682 in Advanced Solid Tumors
Advanced Solid Tumor, Mesothelioma, Malignant
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
Questions about this trial
What is this clinical trial studying?
An observational study of Lung Cancer and Pulmonary Nodule, run by The First Affiliated Hospital of Guangzhou Medical University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 4 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Same-Day Repeatability of the Locked Exhaled-Breath Sampling Method (time frame: During the baseline sampling visit; repeated samples are collected approximately 3-5 minutes apart.). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Sep 2026.